GI Symposium Colorectal Cancer Spotlight | Conferences

Immunotherapy and Targeted Therapy Triplet Active in Microsatellite Stable mCRC

January 27, 2021

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.

Health-Related Quality of Life Low in Younger Colorectal Cancer Survivors

January 18, 2021

The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.

TAS-102 Shows OS Benefit With Bevacizumab in mCRC Ineligible for Intensive Therapy

January 17, 2021

The frontline combination of trifluridine/tipiracil in combination with bevacizumab demonstrated an overall survival benefit compared with capecitabine and bevacizumab as treatment of patients with unresectable metastatic colorectal cancer who are not eligible for a standard chemotherapy regimen, resulting in a difference of almost 5 months, according to the final analysis of the phase 2 TASCO1 trial.

Long-Term Benefit of Pembrolizumab in MSI-H/dMMR mCRC Seen in PFS2, HRQoL

January 16, 2021

The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.